Work

103 Restarting triple therapy with robust monitoring for adverse events (RETRIAL): a prospective, longitudinal, observational study of persons with CF initiating vanzacaftor/tezacaftor/deutivacaftor

Year: 2025

Type: article

Source: Journal of Cystic Fibrosis

DOI: 10.1016/s1569-1993(25)01722-9

Authors: C. Bathgate, K. Riekert, K. Kirby, J. Stoll, J. Boster, E. Tillman, L. Yonker, K. Psoter, J. He, A. Georgiopoulos

Language: English

Topic: Cystic Fibrosis Research Advances

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4414716879

FWCI:

Cites:

Cited by:

Related to: 10